KME GROUP SPA (KME.MI) Fundamental Analysis & Valuation

BIT:KMEIT0004552359

Current stock price

0.88 EUR
-0.01 (-1.12%)
Last:

This KME.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. KME.MI Profitability Analysis

1.1 Basic Checks

  • In the past year KME has reported negative net income.
  • In the past year KME had a positive cash flow from operations.
  • In multiple years KME reported negative net income over the last 5 years.
  • KME had a positive operating cash flow in 4 of the past 5 years.
KME.MI Yearly Net Income VS EBIT VS OCF VS FCFKME.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

  • KME's Return On Assets of -3.14% is on the low side compared to the rest of the industry. KME is outperformed by 77.27% of its industry peers.
  • KME has a Return On Equity of -34.02%. This is amonst the worse of the industry: KME underperforms 84.09% of its industry peers.
  • KME's Return On Invested Capital of 1.20% is on the low side compared to the rest of the industry. KME is outperformed by 63.64% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for KME is significantly below the industry average of 8.77%.
Industry RankSector Rank
ROA -3.14%
ROE -34.02%
ROIC 1.2%
ROA(3y)-1.25%
ROA(5y)1.2%
ROE(3y)-12.27%
ROE(5y)-4.95%
ROIC(3y)1.89%
ROIC(5y)N/A
KME.MI Yearly ROA, ROE, ROICKME.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

  • Looking at the Operating Margin, with a value of 0.96%, KME is doing worse than 68.18% of the companies in the same industry.
  • KME's Operating Margin has declined in the last couple of years.
  • KME's Gross Margin of 27.92% is in line compared to the rest of the industry. KME outperforms 47.73% of its industry peers.
Industry RankSector Rank
OM 0.96%
PM (TTM) N/A
GM 27.92%
OM growth 3YN/A
OM growth 5Y-39.92%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KME.MI Yearly Profit, Operating, Gross MarginsKME.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1

2. KME.MI Health Analysis

2.1 Basic Checks

  • KME has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for KME has been increased compared to 1 year ago.
  • Compared to 5 years ago, KME has less shares outstanding
  • The debt/assets ratio for KME is higher compared to a year ago.
KME.MI Yearly Shares OutstandingKME.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
KME.MI Yearly Total Debt VS Total AssetsKME.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of 0.83, we must say that KME is in the distress zone and has some risk of bankruptcy.
  • KME has a Altman-Z score of 0.83. This is amonst the worse of the industry: KME underperforms 86.36% of its industry peers.
  • The Debt to FCF ratio of KME is 15.00, which is on the high side as it means it would take KME, 15.00 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 15.00, KME is in line with its industry, outperforming 47.73% of the companies in the same industry.
  • KME has a Debt/Equity ratio of 3.00. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 3.00, KME is not doing good in the industry: 93.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3
Debt/FCF 15
Altman-Z 0.83
ROIC/WACC0.12
WACC10.09%
KME.MI Yearly LT Debt VS Equity VS FCFKME.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • KME has a Current Ratio of 0.77. This is a bad value and indicates that KME is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of KME (0.77) is worse than 93.18% of its industry peers.
  • A Quick Ratio of 0.32 indicates that KME may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.32, KME is doing worse than 95.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.32
KME.MI Yearly Current Assets VS Current LiabilitesKME.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

3

3. KME.MI Growth Analysis

3.1 Past

  • KME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.24%, which is quite impressive.
  • Looking at the last year, KME shows a quite strong growth in Revenue. The Revenue has grown by 12.62% in the last year.
  • Measured over the past years, KME shows a very strong growth in Revenue. The Revenue has been growing by 163.60% on average per year.
EPS 1Y (TTM)72.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.55%
Revenue 1Y (TTM)12.62%
Revenue growth 3Y1061.12%
Revenue growth 5Y163.6%
Sales Q2Q%28.64%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KME.MI Yearly Revenue VS EstimatesKME.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2

4. KME.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • KME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KME.MI Price Earnings VS Forward Price EarningsKME.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as KME.
  • Based on the Price/Free Cash Flow ratio, KME is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 5.43
EV/EBITDA 12.43
KME.MI Per share dataKME.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. KME.MI Dividend Analysis

5.1 Amount

  • No dividends for KME!.
Industry RankSector Rank
Dividend Yield 0%

KME.MI Fundamentals: All Metrics, Ratios and Statistics

KME GROUP SPA

BIT:KME (4/20/2026, 7:00:00 PM)

0.88

-0.01 (-1.12%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap250.31M
Revenue(TTM)1.79B
Net Income(TTM)-64.93M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)-63.27%
DP-0.05%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.14
P/FCF 5.43
P/OCF 2.63
P/B 1.31
P/tB N/A
EV/EBITDA 12.43
EPS(TTM)-0.27
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.16
FCFY18.41%
OCF(TTM)0.33
OCFY37.98%
SpS6.3
BVpS0.67
TBVpS-0.91
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -3.14%
ROE -34.02%
ROCE 1.61%
ROIC 1.2%
ROICexc 1.35%
ROICexgc 2.56%
OM 0.96%
PM (TTM) N/A
GM 27.92%
FCFM 2.57%
ROA(3y)-1.25%
ROA(5y)1.2%
ROE(3y)-12.27%
ROE(5y)-4.95%
ROIC(3y)1.89%
ROIC(5y)N/A
ROICexc(3y)2.23%
ROICexc(5y)N/A
ROICexgc(3y)4.95%
ROICexgc(5y)N/A
ROCE(3y)2.52%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y79.58%
ROICexc growth 3YN/A
ROICexc growth 5Y46.15%
OM growth 3YN/A
OM growth 5Y-39.92%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 3
Debt/FCF 15
Debt/EBITDA 8.7
Cap/Depr 100.74%
Cap/Sales 2.73%
Interest Coverage 0.3
Cash Conversion 144.61%
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.32
Altman-Z 0.83
F-Score5
WACC10.09%
ROIC/WACC0.12
Cap/Depr(3y)57.3%
Cap/Depr(5y)69.14%
Cap/Sales(3y)1.76%
Cap/Sales(5y)10.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.55%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.62%
Revenue growth 3Y1061.12%
Revenue growth 5Y163.6%
Sales Q2Q%28.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y195.37%
EBIT growth 3YN/A
EBIT growth 5Y58.36%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-62.16%
FCF growth 3Y16.77%
FCF growth 5YN/A
OCF growth 1Y-34.19%
OCF growth 3Y29.71%
OCF growth 5YN/A

KME GROUP SPA / KME.MI Fundamental Analysis FAQ

What is the fundamental rating for KME stock?

ChartMill assigns a fundamental rating of 2 / 10 to KME.MI.


Can you provide the valuation status for KME GROUP SPA?

ChartMill assigns a valuation rating of 2 / 10 to KME GROUP SPA (KME.MI). This can be considered as Overvalued.


What is the profitability of KME stock?

KME GROUP SPA (KME.MI) has a profitability rating of 1 / 10.


How financially healthy is KME GROUP SPA?

The financial health rating of KME GROUP SPA (KME.MI) is 1 / 10.